top
Search terms
Results 1 - 10 of 92 - ordered by :
Pages: 1 2 3 4 5 6 7 ... 10
Escardio

Vigorous physical activity one or two times a week is associated with the lowest death rates in patients with stable coronary artery disease, reports a study published today in the European Journal ...

Date : 27/09/2019
Escardio

The risk of death is highest in the first 6 months following myocardial infarction (MI).1,2 However, current ESC Guidelines recommend a delay of at least 6 weeks after MI before considering ...

Date : 04/09/2019
Escardio

“Poor sleep quality has been linked to elevated blood pressure and the development of hypertension, but here at ESC Congress yesterday, Sasaki et al presented an observational study in 3,313 ...

Date : 03/09/2019
Escardio

Chest pain and prior heart attack is a dangerous duet in stable coronary artery disease Angina in patients with a previous heart attack is linked with a poor outcome in patients with stable coronary ...

Date : 03/09/2019
Escardio

Early use of an implantable cardioverter-defibrillator (ICD) after primary coronary intervention lengthens survival in patients at high risk of death after ST-segment elevation myocardial infarction ...

Date : 03/09/2019
Escardio

Genotype-guided oral P2Y12 inhibition reduces bleeding without raising clotting risk in heart attack patients undergoing stent implantation, according to late breaking results from the POPular ...

Date : 03/09/2019
Escardio

ESC guidelines recommend a short period of triple therapy (oral anticoagulant, aspirin, clopidogrel) followed by a period of dual therapy (oral anticoagulant plus aspirin or clopidogrel) in atrial ...

Date : 03/09/2019
Escardio

Professor Deepak L. Bhatt (Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA) describes the rationale for the study, which is the largest trial in type 2 ...

Date : 02/09/2019
Escardio

(7) The study therefore used an innovative social marketing campaign to introduce a new product called Salt-Liz, a name chosen and approved by locals. Among the 1,865 participants (79%) without ...

Date : 02/09/2019
Escardio

Over a median follow-up of 18.2 months, the primary outcome occurred in 386 of 2,373 patients (16.3%) in the dapagliflozin group and in 502 of 2,371 patients (21.2%) in the placebo group (hazard ...

Date : 01/09/2019